Filing Flows › Zoetis (ZTS) › Guidance & outlook
Zoetis (ZTS) guidance and outlook
Zoetis (ZTS) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $9.2B–$9.3B for FY2026; Revenue −2% to −1% for FY2026; Net income $2.6B for FY2026; Net income −7% to −5% for FY2026. Zoetis' 10-Q filed Nov 5, 2026 makes 15 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $9.2B–$9.3B | raised |
| Revenue | FY2026 | −2% to −1% | raised |
| Net income | FY2026 | $2.6B | raised |
| Net income | FY2026 | −7% to −5% | raised |
| EPS | FY2026 | $6.25–$6.35 | raised |
| Tax rate | FY2026 | 20% | lowered |
| EPS | FY2026 | $6.25–$6.35 | raised |
| Net income | FY2026 | −7% to −5% | raised |
From the earnings release filed Nov 5, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 5, 2026
- We will continue to actively monitor the situation and evaluate actions that can be taken to moderate and/or minimize its effects, including seeking refunds related to prior tariff assessments where applicable.
- Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products.
- As we operate in multiple foreign currencies, including the Australian dollar, Brazilian real, British pound, Canadian dollar, Chinese renminbi, euro and other currencies, changes in those currencies relative to the U.S. dollar will impact our revenue, cost of goods and expenses, and consequently, net income.
- In addition, we plan to recast the consolidated financial statements as of and for the twelve months ended December 31, 2025 and 2024 when they are presented as comparatives in future financial statements.
- As a result of the Fiscal Year Alignment, the results of operations of our International Subsidiaries for the month of December 2025 will not be included in our consolidated results of operations for fiscal year 2026 but will be included in the retrospective application of the new accounting principle to prior financial statement periods.
- Other business activities net loss decreased by $9 million in the three months ended September 30, 2026, compared with the three months ended September 30, 2025, reflecting a decrease in R&D costs related to projects and other strategic investments, as well as higher earnings from our contract manufacturing business.
- Other business activities net loss increased by $5 million in the nine months ended September 30, 2026, compared with the nine months ended September 30, 2025, reflecting an increase in R&D costs related to projects and other strategic investments, as well as lower earnings from our human health and contract manufacturing businesses.
- We have not factored in the impact of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances.
- Unusual, in this context, may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be nonrecurring; or items that relate to products that we no longer sell.
- This comprehensive program is a major global and cross-functional company-wide effort, of which the Fiscal Year Alignment is a part, that we believe will transform how we work across our business and contribute to all of our strategic priorities.
- Our assessment is based on such factors as past due aging, historical and expected collection patterns, the financial condition of our customers, the robust nature of our credit and collection practices and the economic environment.
- Challenging economic conditions in recent years have not had, nor do we anticipate that they will have, a significant impact on our liquidity.
Zoetis' latest quarter
Zoetis, Q3 2026: revenue $2.4B (-1% year over year), operating margin 30.5%, net earnings $591M, operating cash flow $824M. The chart follows the revenue to costs, profit and cash.
Questions
Did Zoetis raise or lower its guidance?
Zoetis (ZTS) raised some and lowered other parts of its guidance on Nov 5, 2026: Revenue $9.2B–$9.3B for FY2026; Revenue −2% to −1% for FY2026; Net income $2.6B for FY2026; Net income −7% to −5% for FY2026.
What does Zoetis expect?
We will continue to actively monitor the situation and evaluate actions that can be taken to moderate and/or minimize its effects, including seeking refunds related to prior tariff assessments where applicable. Outbreaks of disease may reduce regional or global sales of particular animal-derived food products or result in reduced exports of such products, either due to heightened export restrictions or import prohibitions, which may reduce demand for our products. As we operate in multiple foreign currencies, including the Australian dollar, Brazilian real, British pound, Canadian dollar, Chin
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.